Catherine R Garcia1, Stacey A Slone1, Monica Chau2, Janna H Neltner3, Thomas Pittman4, John L Villano5. 1. Markey Cancer Center, University of Kentucky, Lexington, KY, United States. 2. Department of Neurology, University of Kentucky, Lexington, KY, United States. 3. Departments of Pathology, Division of Neuropathology, University of Kentucky, Lexington, KY, United States. 4. Departments of Neurosurgery, University of Kentucky, Lexington, KY, United States. 5. Department of Medicine, University of Kentucky, Lexington, KY, United States; Department of Neurology, University of Kentucky, Lexington, KY, United States; Departments of Neurosurgery, University of Kentucky, Lexington, KY, United States; Markey Cancer Center, University of Kentucky, Lexington, KY, United States. Electronic address: jlvillano@uky.edu.
Abstract
BACKGROUND: Meningiomas are the most common central nervous system tumor. We describe current trends in treatment and survival using the largest cancer dataset in the United States. METHODS: We analyzed the National Cancer Database from 2004 to 2014, for all patients with diagnosis of meningioma. RESULTS: 201,765 cases were analyzed. Patients were most commonly White (81.9%) females (73.2%) with a median age of 64 years. Fifty percent of patients were diagnosed by imaging. Patients were reported as grade I (24.9%), grade II (5.0%), grade III (0.7%), or unknown WHO grade (69.4%). Patients diagnosed by imaging were older, received treatment in community facilities, had higher Charlson-Deyo score, and a lower rate of private insurance. Watchful waiting was the most common treatment modality (46.7%), followed by surgery only (40%). Grade II and III patients were more likely to receive therapy. Watchful waiting increased from 35.2% in 2004 to 51.4% in 2014. Younger age, male gender, private insurance, and treatment in academic facilities were determinants for receipt of surgery and/or radiation. Median survival was 12.6 years, higher in histologically confirmed cases (13.1 years). Older patients, Blacks, males, those that received radiation plus surgery, and were treated in community facilities had an increased risk of mortality. CONCLUSIONS: Over half of patients were diagnosed by imaging, suggesting a higher role of clinical determinants over histological confirmation in treatment decisions. Watchful waiting as initial management is increasing. Our survival analysis favored histological confirmation. Patients receiving radiation and surgery had an increased risk of mortality.
BACKGROUND:Meningiomas are the most common central nervous system tumor. We describe current trends in treatment and survival using the largest cancer dataset in the United States. METHODS: We analyzed the National Cancer Database from 2004 to 2014, for all patients with diagnosis of meningioma. RESULTS: 201,765 cases were analyzed. Patients were most commonly White (81.9%) females (73.2%) with a median age of 64 years. Fifty percent of patients were diagnosed by imaging. Patients were reported as grade I (24.9%), grade II (5.0%), grade III (0.7%), or unknown WHO grade (69.4%). Patients diagnosed by imaging were older, received treatment in community facilities, had higher Charlson-Deyo score, and a lower rate of private insurance. Watchful waiting was the most common treatment modality (46.7%), followed by surgery only (40%). Grade II and III patients were more likely to receive therapy. Watchful waiting increased from 35.2% in 2004 to 51.4% in 2014. Younger age, male gender, private insurance, and treatment in academic facilities were determinants for receipt of surgery and/or radiation. Median survival was 12.6 years, higher in histologically confirmed cases (13.1 years). Older patients, Blacks, males, those that received radiation plus surgery, and were treated in community facilities had an increased risk of mortality. CONCLUSIONS: Over half of patients were diagnosed by imaging, suggesting a higher role of clinical determinants over histological confirmation in treatment decisions. Watchful waiting as initial management is increasing. Our survival analysis favored histological confirmation. Patients receiving radiation and surgery had an increased risk of mortality.
Authors: Quinn T Ostrom; Haley Gittleman; Jordan Xu; Courtney Kromer; Yingli Wolinsky; Carol Kruchko; Jill S Barnholtz-Sloan Journal: Neuro Oncol Date: 2016-10-01 Impact factor: 12.300
Authors: Nicholas R Rydzewski; Maciej S Lesniak; James P Chandler; John A Kalapurakal; Erqi Pollom; Matthew C Tate; Orin Bloch; Timothy Kruser; Prarthana Dalal; Sean Sachdev Journal: Cancer Date: 2017-11-13 Impact factor: 6.860
Authors: Ayal A Aizer; Wenya Linda Bi; Manjinder S Kandola; Eudocia Q Lee; Lakshmi Nayak; Mikael L Rinne; Andrew D Norden; Rameen Beroukhim; David A Reardon; Patrick Y Wen; Ossama Al-Mefty; Nils D Arvold; Ian F Dunn; Brian M Alexander Journal: Cancer Date: 2015-08-26 Impact factor: 6.860
Authors: Leland Rogers; Peixin Zhang; Michael A Vogelbaum; Arie Perry; Lynn S Ashby; Jignesh M Modi; Anthony M Alleman; James Galvin; David Brachman; Joseph M Jenrette; John De Groot; Joseph A Bovi; Maria Werner-Wasik; Jonathan P S Knisely; Minesh P Mehta Journal: J Neurosurg Date: 2017-10-06 Impact factor: 5.115
Authors: Ziming Du; Malak Abedalthagafi; Ayal A Aizer; Allison R McHenry; Heather H Sun; Mark-Anthony Bray; Omar Viramontes; Revaz Machaidze; Priscilla K Brastianos; David A Reardon; Ian F Dunn; Gordon J Freeman; Keith L Ligon; Anne E Carpenter; Brian M Alexander; Nathalie Y Agar; Scott J Rodig; Elizabeth M Bradshaw; Sandro Santagata Journal: Oncotarget Date: 2015-03-10